Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYLARIFY PET-CT for Detecting Metastasis in Pancreatic, Hepatocellular, and Breast Cancers
NCT05394259Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of piflufolastat f 18 in pancreatic cancer (PC), hepatocellular carcinoma (HCC) and breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Diagnostic Accuracy at 1 year. Started Oct 2022; status: active, not recruiting.
02
Drugs
piflufolastat f 18
03
Conditions
pancreatic cancer (PC)hepatocellular carcinoma (HCC)breast cancer
Beyond the preview
Go deeper on NCT05394259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394259.